dc.description.abstract |
on their comparative efficacy across different vaccine types and chicken breeds.
Therefore, this experimental study was conducted from October 2024 to January 2025 at
the Andassa Livestock Research Center poultry farm to evaluate the humoral antibody
response of NCD vaccines in Tillili and Koekoek chicken breeds.The study comapared
three vaccines (I2 thermostable, LaSota, and HB1) along with a positive control. The
specific objectives of the study were to evaluate the antibody responses to the three
vaccines and the positive control in both breeds, to identify risk factors associated with
variations in antibody responses,to determine the magnitude of mortality and survival of
chickens and to assess differences in maternally-derived antibody levels between the
Tillili and Koekoek breeds. A Completely Randomized Design with a 2x4 factorial
arrangement was employed. A total of 480 day-old chicks (DOCs), comprising 240
indigenous Tillili and 240 exotic Koekoek, were randomly assigned to 24 pens (20
birds/pen). A total of 1,092 blood samples were collected one day before and 14 days
after each vaccination, with 964 samples successfully processed. Antibody titers against
NCD were quantified using an indirect ELISA. Independent and paired t-tests were used
to compare mean antibody titers between the treatment and control groups before and
after vaccination, respectively. Additionally, multiple linear regression, and Cox
regression were used to evaluate and quantify the effect of covariates on mean antibody
titer and chicken mortality rates, respectively. The overall chick mortality percentage
across all treatment groups was 4.6%. During the study period, 76% of chickens
developed protective antibody levels against NCD across the four treatments. Koekoek
chickens exhibited significantly higher maternal antibody levels (mean titer 4,460.3)
compared to Tillili chickens (mean titer 202.3) during the first week of life. A relatively
higher antibody response (5475.4 ± 2821.1) was also detected in Koekoek compared to
Tillili (4200.9 ± 2092.8. Overall, antibody responses were higher at 42days postvaccination
with thermosatble vaccines (6031.2±420.2), Comparison of vaccine types
revealed significant differences in antibody levels before and after vaccination among
bleeding dates (P = 0.0274) and between treatment groups (P = 0.0002). However, an
independent t-test comparing the positive control and treatment groups revealed no
significant difference (P=0.1954) in antibody responses. The Multiple linear regression
revealed that sex (P = 0.0172), bleeding time (P = 0.001), and age (P = 0.000) were
statistically significant with mean antibody titer. In conclusion, all three vaccines elicited
protective immunity, with the positive control achieving relatively the highest efficacy,
followed by the thermostable vaccine. This suggests that the thermostable vaccine
demonstrates comparable practical advantages for field use, especially in areas where
cold chains are limited. |
en_US |